Resumption Dates for WHO FCTC COP10 and MOP3 Announced

Events by 2FIRSTS.ai
Nov.29.2023
Resumption Dates for WHO FCTC COP10 and MOP3 Announced
The World Health Organization has announced the resumption dates for the COP10 and MOP3 meetings in 2024.

According to an announcement from the World Health Organization on November 27th, the resumption dates for the Tenth Session of the Conference of the Parties to the WHO Framework Convention on Tobacco Control (COP10) and the Third Session of the Meeting of the Parties to the Protocol to Eliminate Illicit Trade in Tobacco Products (MOP3) have been scheduled for February 5th, 2024.

 

In the announcement, it was mentioned that after consultation with the host country Panama, the resumption dates for COP10 and MOP3 have been confirmed. The specific schedule is as follows:

 

The COP10 meeting of the WHO Framework Convention on Tobacco Control will resume from Monday, February 5, 2024 to Saturday, February 10, 2024. The MOP3 meeting of the Protocol to Eliminate Illicit Trade in Tobacco Products will resume from Monday, February 12, 2024 to Thursday, February 15, 2024. The World Health Organization expressed its anticipation for the participation of all contracting parties in the upcoming supervisory meetings of the WHO Framework Convention on Tobacco Control and the Protocol to Eliminate Illicit Trade in Tobacco Products. The Secretariat of the conventions, in collaboration with the host country, remains committed to the life-saving work of tobacco control.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | Refillable up to 30 mL in total and claimed 60,000 puffs: MASKKING launches open-system UCEE MAX
Product | Refillable up to 30 mL in total and claimed 60,000 puffs: MASKKING launches open-system UCEE MAX
E-cigarette brand MASKKING has recently listed its new UCEE MAX on its official website. According to the website, the device features an open, refillable design with a stated 10 mL e-liquid capacity, supports three refills, and claims a total of 60,000 puffs.
Mar.02 by 2FIRSTS.ai
Reuters Exclusive: FDA’s Fast-Track Review of Nicotine Pouches Slows Over Youth and New-User Concerns
Reuters Exclusive: FDA’s Fast-Track Review of Nicotine Pouches Slows Over Youth and New-User Concerns
Reuters reported on April 1 that several popular nicotine pouch products still have not been cleared for sale in the United States despite a fast-track review pilot run by the U.S. Food and Drug Administration. Three sources said FDA reviewers have taken a cautious approach because of potential risks to youth and other non-tobacco users, including the possibility of driving nicotine addiction among adults who do not already smoke.
Apr.02 by 2FIRSTS.ai
Australia’s Tasmania Tables New Bill to Strengthen Crackdown on Illicit Tobacco and Vapes
Australia’s Tasmania Tables New Bill to Strengthen Crackdown on Illicit Tobacco and Vapes
The Tasmanian government has tabled the Public Health Amendment (Prohibited Tobacco and Other Products) Bill 2026 in Parliament, proposing new offences, higher penalties and stronger enforcement powers to crack down on illicit tobacco and vaping products.
Mar.25 by 2FIRSTS.ai
IMF Article Sets Out Three Principles: Cover All Harmful Products, Match Tax Rates to Harm, Improve Cross-Border Coordination
IMF Article Sets Out Three Principles: Cover All Harmful Products, Match Tax Rates to Harm, Improve Cross-Border Coordination
A March 2026 article in Finance & Development, “Taxing Harmful Habits,” argues that taxes on harmful products such as tobacco, alcohol and sugary drinks should better reflect the health harm they cause. The authors propose three principles: capture all harmful products, align tax rates with health harm, and strengthen cross-border coordination to reduce evasion and smuggling.
Mar.24 by 2FIRSTS.ai
Special Report | Middle East Military Conflict Disrupts Global Air Corridors: Europe-Bound Vape Logistics Defy Seasonal Price Declines, Fuel Cost Risks Emerge
Special Report | Middle East Military Conflict Disrupts Global Air Corridors: Europe-Bound Vape Logistics Defy Seasonal Price Declines, Fuel Cost Risks Emerge
Escalating tensions involving Iran are disrupting air transit routes heavily used for China’s vape exports to Europe, preventing the usual post–Lunar New Year freight rate decline. While Europe-bound capacity reliant on Middle East hubs faces pressure, shipments to the United States remain largely unaffected for now. However, potential jet fuel price increases could broaden cost pressures globally.
Special Report
Mar.02
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24